Brand Name

Kymirah

Breyanzi

Yescarta

Abecma

Tecartus

Reference

Proper Name

Tisagenlecleucel

Lisocabtagene maraleucel

Axicabtagene ciloleucel

Idecabtagene vicleucel

Brexucabtagene autoleucel

[41]

Approval Date

1^st May, 2018

5^th February, 2021

5^th March, 2021

26^th March, 2021

1^st October, 2021

Manufacturer

Novartis Pharmaceuticals

Juno Therapeutics Inc.

Kite Pharma Inc.

Celgene Corporation

Kite Pharma Inc.

Indication

1. Young and pediatric adult patient (3 - 25) years with B cell precursor ALL

2. Adult patient with R/R large B cell lymphoma

1. Elderly patient with R/R large B cell lymphoma

2. Diffuse large B cell lymphoma

1. Old patient with R/R follicular lymphoma after two or more lines of systemic therapy

1. Geriatric patient with R/R multiple myeloma

1. Adult patient with R/R B cell precursor ALL

2. R/R MCL